new life expectancy table

annals of intern med had article this week reviewing a 5% sample of medicare beneficiaries over 65 years old in different geographical areas and used claims data to assess comorbidities and subsequent survival, creating an updated and more extensive table (see life expectancy table annals 2013 in dropbox, or doi:10.7326/0003-4819-159-10-201311190-00005). people with hx of cancer were excluded.  the table is reproduced below.

a couple of issues. 
    --the sample reviewed may not reflect the entire elderly population, since it included fee-for-service medicare only. 
    --one intention of the study was to provide us guys with a way to assess when to stop health screening, perhaps limiting future mammograms or colonoscopy to those who have a reasonable 5 to 10-year survival.  one concern here is that there are no real screening data on people over 70-75 years old (studies not done), so we are left with mathematical modeling, which applies the conclusions for screening younger people (ie that they benefit after 5-10 with early detection of cancer) to the untested older patients. but there are questions about this: eg, is the pathophysiology the same in older vs younger patients (ie, does the breast or colon cancer act the same/follow the same course -- i'm not sure here), are the complications of the test the same (here there are data showing that the yield of colonoscopy decreases significantly in those over 75, and the likelihood of colonic perforation increases), are the effects on quality of life the same (elderly bounce back less quickly from an invasive procedure, either because they need a breast bx, or just the colonoscopy itself), do the elderly tolerate the therapy for a detected cancer enough to justify finding one, etc, etc.  that being said, i think most of us do continue with screening in older patients with good life expectancy (eg an 80 yo white woman in good health has life expectancy of 11.7 years .... by the way, from this table an 85 yo in good health has the same life expectancy as 66yo with CHF)
    --i think it is really useful for us as providers to have a sense of life expectancy anyway, not just for screening, but also in terms of the immediacy of end-of-life planning, ability to talk with the patient about their life expectancy and planning, answer more accurately patient/family questions on prognosis, etc


Image not available.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more